Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

DEprescrição no tratamento paliativo do câncer: percepções dos pacientes (DEPAL)

22 de setembro de 2026 atualizado por: Nantes University Hospital

DEprescrição no tratamento paliativo do câncer: percepções dos pacientes: um estudo observacional misto prospectivo e multicêntrico

Polymedication in palliative oncology care is a real public health problem. This phenomenon has been shown to increase the risk of iatrogenesis, reduce patients' quality of life and increase healthcare costs. For many years, health policies have been developed in geriatrics to reduce polymedication through deprescription tools.

Recently, palliative care initiatives have been introduced, but without having studied the potential specificities of this population (younger, with a different care dynamic and life trajectory). It is important to better understand this population's perceptions of deprescribing in order to adapt tools/actions to make these approaches more efficient.

The primary aim of this study is to investigate patients' perceptions of deprescribing in palliative cancer care, and the secondary aim is to investigate factors that may influence patients' attitudes and beliefs about deprescribing. At the same time, we will study the psychometric properties of the rPATD (Revised Patients' Attitudes Towards Deprescribing) in this population (a standardized questionnaire validated in geriatric medicine to assess patients' perceptions of deprescription).An ancillary study will be carried out to investigate the link between patients' health literacy and their perception of deprescribing (health literacy is defined as the ability to acquire, understand and use information in ways that promote and maintain good health).

To meet our objectives, we will conduct a 3-year national, prospective, observational, multicenter study with an exploratory sequential mixed design. The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period). Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period).The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy.

Thanks to the different results, we will improve our knowledge of the perception of deprescription in palliative oncology care, in order to develop approaches adapted to the specificities of our population to reduce polymedication and thus improve the quality of life of our patients and reduce the risks of iatrogenia.

Visão geral do estudo

Tipo de estudo

Observacional

Inscrição (Estimado)

325

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • La Roche-sur-Yon, França, 85000
        • Ainda não está recrutando
        • CHD Vendée
        • Contato:
      • Lyon, França
        • Ainda não está recrutando
        • Hospices Civils de Lyon
        • Contato:
        • Investigador principal:
          • Guillaume ECONOMOS, MD
      • Nantes, França, 44093
        • Recrutamento
        • CHU de Nantes
        • Contato:
        • Investigador principal:
          • Adrien EVIN, MCU-PH
        • Subinvestigador:
          • Yann TOUCHEFEU, PU-PH
        • Subinvestigador:
          • André COLPAERT, PH
        • Subinvestigador:
          • Elvire PONS-TOSTIVIN, MCU-PH
        • Subinvestigador:
          • Gaëlle QUEREUX BAUMGARTNER, MCU-PH
      • Nantes, França
        • Ainda não está recrutando
        • USP - Maison de Nicodème
        • Contato:
        • Investigador principal:
          • Benjamin CHARTIER, MD
      • Paris, França, 75005
        • Ainda não está recrutando
        • Hôpital Institut CURIE
        • Contato:
        • Investigador principal:
          • Stéphanie Träger
      • Saint-Herblain, França, 44800
        • Ainda não está recrutando
        • Institut de Cancérologie de l'Ouest
        • Contato:
        • Investigador principal:
          • BARBAROT Véronique
      • Saint-Nazaire, França, 44600
        • Ainda não está recrutando
        • CH ST Nazaire
        • Contato:
        • Investigador principal:
          • Virginie DESSUS-CHEVREL, PH
      • Tours, França

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

We'll be looking at major patients with "solid" cancer in a palliative situation (locally advanced or metastatic cancer, thus requiring palliative care as defined by the World Health Organization), who have at least one PIMs, followed up on an inpatient or outpatient basis, with a life expectancy estimated at less than 1 year by the doctor caring for the patient.

To identify whether a patient has at least one PIMs, we will use the STOPPFrail 2 tool . This is a tool developed in geriatrics, validated for a population with an estimated life expectancy of less than 1 year, and which is not specific to oncology. Life expectancy of less than one year will be estimated by the question surprised by the doctor caring for the patient ("Would you be surprised if your patient died within a year?") .

We will carry out a multicenter study in oncology and/or palliative care departments of hospitals located in western France.

Descrição

Inclusion Criteria:

  • Patient over 18 years of age
  • Locally advanced or metastatic solid cancer (i.e., palliative care as defined by the World Health Organization)
  • Life expectancy estimated by the physician at inclusion of less than 1 year (use of surprise question to help clinician estimate life expectancy)
  • Hospitalized or in consultation
  • With at least one PIMs (identified using STOPPfrail 2)
  • Patient not having expressed opposition to participating in the study after receiving information from the physician.

For qualitative study patients :

- Patients who have signed an authorization for the recording of their voice during the semi-structured interview for the purpose of written transcription.

Exclusion Criteria:

  • Minor
  • Major under guardianship, protected person
  • Patient unable to speak or write French
  • Patient with impaired judgment, cognitive or sensory impairment that prevents him/her from receiving informed information, answering questionnaires or participating in a study interview.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: CASE_ONLY
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Qualitative study

The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period).

Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)

Quantitative study

Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period).

The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy.

rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.

This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal). Following the analysis of Phase 1 "Qualitative" of the protocol, three additional questions

BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .

The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.

It comprises 10 items relating to specific beliefs about prescribed treatments:

A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief.

FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )

Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :

Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
To study patients' perceptions of deprescribing in palliative cancer care.
Prazo: at study inclusion

To describe, understand and explain patients' attitudes and beliefs concerning deprescribing by means of individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis) and secondly using the rPATD questionnaire (questionnaire for assessing patients' perceptions of their treatments and deprescribing), which can be adapted following analysis of qualitative data.

rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.

This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale

at study inclusion

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
To investigate factors that may influence patients' attitudes and beliefs regarding de-prescribing.
Prazo: at study inclusion

Influence of gender, age, level of education, type of cancer, number of metastatic sites, Performans status score, presence of systemic cancer treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, etc.), follow-up by a palliative care team, and other factors. ), follow-up by a palliative care team, patient's place of care, persons in charge of treatment, number of medications, number of potentially inappropriate medications (PIMs), prognosis assessed by the referring physician, patient's level of education and beliefs about treatments in general (BMQ questionnaire) on scores from the rPATD questionnaire.

at study inclusion
To evaluate the psychometric properties of the rPATD in this population.
Prazo: at study inclusion

Description of rPATD validation data in our population: validation of questionnaire structure, measurement of score reliability, concurrent validation with the BMQ questionnaire.

BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .

A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief.

at study inclusion

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
ANCILLARY STUDY
Prazo: at study inclusion

For patients who wish to do so (depending on their fatigability), we will study the link between patients' level of health literacy and their perception of deprescribing (health literacy is defined as the ability to acquire, understand and use information in ways that promote and maintain good health ).

To do this, we will assess the link between patients' level of literacy (using the FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale) self-questionnaire) and their perception of deprescription.

at study inclusion

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Adrien EVIN, Nantes University Hospital

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

28 de fevereiro de 2024

Conclusão Primária (Real)

28 de fevereiro de 2025

Conclusão do estudo (Estimado)

4 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

21 de dezembro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

4 de janeiro de 2024

Primeira postagem (Real)

5 de janeiro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever